$32.47 Million in Sales Expected for Atara Biotherapeutics, Inc. (NASDAQ:ATRA) This Quarter

Analysts expect Atara Biotherapeutics, Inc. (NASDAQ:ATRA) to announce $32.47 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Atara Biotherapeutics’ earnings, with the highest sales estimate coming in at $50.60 million and the lowest estimate coming in at $3.87 million. The company is scheduled to report its next earnings report on Monday, March 7th.

According to Zacks, analysts expect that Atara Biotherapeutics will report full year sales of $44.53 million for the current fiscal year, with estimates ranging from $15.16 million to $63.40 million. For the next financial year, analysts anticipate that the firm will report sales of $49.62 million, with estimates ranging from $18.80 million to $73.70 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Thursday, November 4th. The biotechnology company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.02. During the same period last year, the business earned ($0.92) earnings per share.

Several analysts have commented on the company. Stifel Nicolaus lowered their price target on Atara Biotherapeutics from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, October 4th. Zacks Investment Research lowered Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, November 11th. HC Wainwright reaffirmed a “buy” rating and issued a $31.00 price target on shares of Atara Biotherapeutics in a research note on Tuesday, October 5th. Finally, Mizuho assumed coverage on Atara Biotherapeutics in a research note on Wednesday, October 13th. They issued a “buy” rating and a $41.00 price target on the stock. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $28.25.

In other Atara Biotherapeutics news, Director Matthew K. Fust sold 13,354 shares of Atara Biotherapeutics stock in a transaction on Thursday, November 4th. The stock was sold at an average price of $19.50, for a total value of $260,403.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Pascal Touchon sold 8,402 shares of Atara Biotherapeutics stock in a transaction on Tuesday, November 16th. The shares were sold at an average price of $17.12, for a total value of $143,842.24. The disclosure for this sale can be found here. In the last quarter, insiders have sold 55,734 shares of company stock worth $977,849. 3.80% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Geneos Wealth Management Inc. acquired a new stake in shares of Atara Biotherapeutics in the first quarter valued at $30,000. Macquarie Group Ltd. grew its stake in shares of Atara Biotherapeutics by 326.1% in the third quarter. Macquarie Group Ltd. now owns 3,311 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 2,534 shares in the last quarter. NEXT Financial Group Inc acquired a new stake in shares of Atara Biotherapeutics in the second quarter valued at $105,000. Dark Forest Capital Management LP acquired a new stake in shares of Atara Biotherapeutics in the second quarter valued at $117,000. Finally, Point72 Hong Kong Ltd grew its stake in Atara Biotherapeutics by 1,155.2% during the 3rd quarter. Point72 Hong Kong Ltd now owns 7,845 shares of the biotechnology company’s stock worth $140,000 after purchasing an additional 7,220 shares in the last quarter.

ATRA traded up $0.08 during trading on Thursday, hitting $18.15. The company’s stock had a trading volume of 340,461 shares, compared to its average volume of 845,939. Atara Biotherapeutics has a twelve month low of $11.81 and a twelve month high of $28.20. The business’s fifty day moving average price is $16.95. The company has a market cap of $1.60 billion, a price-to-earnings ratio of -5.01 and a beta of 2.03.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need.

See Also: What is the return on assets formula?

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.